605 related articles for article (PubMed ID: 25952490)
61. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
62. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
63. Chemotherapy for treatment of grade II gliomas.
Strowd RE; Holdhoff M; Grossman SA
Oncology (Williston Park); 2014 Dec; 28(12):1036-43. PubMed ID: 25510803
[TBL] [Abstract][Full Text] [Related]
64. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
[TBL] [Abstract][Full Text] [Related]
65. Chemotherapy of Oligodendrogliomas.
Drappatz J; Lieberman F
Prog Neurol Surg; 2018; 31():152-161. PubMed ID: 29393183
[TBL] [Abstract][Full Text] [Related]
66. [Favourable result for temozolomide in recurrent high-grade glioma].
Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
[TBL] [Abstract][Full Text] [Related]
67. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
68. Neuro-oncology: the growing role of chemotherapy in glioma.
Carpentier AF
Lancet Neurol; 2005 Jan; 4(1):4-5. PubMed ID: 15620846
[No Abstract] [Full Text] [Related]
69. Bevacizumab is active as a single agent against recurrent malignant gliomas.
Agha CA; Ibrahim S; Hassan A; Elias DA; Fathallah-Shaykh HM
Anticancer Res; 2010 Feb; 30(2):609-11. PubMed ID: 20332478
[TBL] [Abstract][Full Text] [Related]
70. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
[TBL] [Abstract][Full Text] [Related]
71. [Therapeutic strategies for the management of gliomas].
Hottinger AF; Stupp R
Rev Neurol (Paris); 2008; 164(6-7):523-30. PubMed ID: 18565350
[TBL] [Abstract][Full Text] [Related]
72. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
[TBL] [Abstract][Full Text] [Related]
73. Anaplastic oligodendroglial tumors: a tale of two trials.
Gilbert MR; Lang FF
J Clin Oncol; 2006 Jun; 24(18):2689-90. PubMed ID: 16782906
[No Abstract] [Full Text] [Related]
74. Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Mazzocco P; Honnorat J; Ducray F; Ribba B
Comput Math Methods Med; 2015; 2015():297903. PubMed ID: 26788118
[TBL] [Abstract][Full Text] [Related]
75. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
de Wit MC; de Bruin HG; Eijkenboom W; Sillevis Smitt PA; van den Bent MJ
Neurology; 2004 Aug; 63(3):535-7. PubMed ID: 15304589
[TBL] [Abstract][Full Text] [Related]
76. Low-grade oligodendroglioma responds to chemotherapy.
Mason WP; Krol GS; DeAngelis LM
Neurology; 1996 Jan; 46(1):203-7. PubMed ID: 8559376
[TBL] [Abstract][Full Text] [Related]
77. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Strowd RE; Abuali I; Ye X; Lu Y; Grossman SA
J Neurooncol; 2016 Mar; 127(1):165-71. PubMed ID: 26729269
[TBL] [Abstract][Full Text] [Related]
78. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Cairncross G; Swinnen L; Bayer R; Rosenfeld S; Salzman D; Paleologos N; Kaminer L; Forsyth P; Stewart D; Peterson K; Hu W; Macdonald D; Ramsay D; Smith A;
Neuro Oncol; 2000 Apr; 2(2):114-9. PubMed ID: 11303620
[TBL] [Abstract][Full Text] [Related]
79. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
[TBL] [Abstract][Full Text] [Related]
80. Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.
van den Bent MJ
Semin Oncol; 2003 Dec; 30(6 Suppl 19):39-44. PubMed ID: 14765384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
